Mayo Clinic Comprehensive Cancer Center and Columbia University received a five-year, $10.6 million U54 center grant from the National Cancer Institute (NCI) to further study combining the ...
UNC Health is now enrolling patients as part of a multicenter clinical trial for patients who have been newly diagnosed ...
HOUSTON ― A team of researchers at The University of Texas MD Anderson Cancer Center has developed a new method ...
Glioblastoma is the most common type of brain tumor that affects adults and, unfortunately, still remains incurable. In a new ...
Scientists have created a new zebrafish xenograft platform to screen for novel treatments for an aggressive brain tumor called glioblastoma, ...
MIAMI, FLORIDA (STRICTLY EMBARGOED UNTIL SEPT. 29, 2023 AT 5PM ET) – Is it true progression or pseudoprogression in tumor ...
EMBARGOED: September 18, 2023 4PM EST CONTACT: Nicole Oliverio, nicole_oliverio@dfci.harvard.edu, 617-257-0454 Boston – An innovative phase 2 clinical trial led ...
The discovery of a previously unknown molecular target has inspired what may become a therapeutic breakthrough for people with glioblastoma, ...
Vibrant green leaves sprout from tall fragrant plants sitting neatly in two rows of terracotta pots in Valerie Sponsel’s UTSA ...
Lawrence Pfeffer, PhD, Professor in the Department of Pathology at the University of Tennessee Health Science Center, recently was awarded $2.56 ...
Glioblastoma (GBM) is the most aggressive and lethal form of brain tumor. Despite treatment, GBM recurrence is inevitable and tends ...
In a recently published manuscript, Howard Colman, MD, PhD, Jon M. Huntsman Presidential Professor of Neuro-Oncology and co-leader of the Neurologic ...
SAN ANTONIO (May 23, 2023) — The Mays Cancer Center at The University of Texas Health Science Center at San ...
BUFFALO, NY- May 19, 2023 – A new research perspective was published in Oncotarget's Volume 14 on May 4, 2023, ...
TORONTO - A new international study published in Nature Medicine and presented as a late-breaking abstract at the American Association ...
HOUSTON ― Intratumoral delivery of an engineered oncolytic virus (DNX-2401) targeting glioblastoma (GBM) cells combined with subsequent immunotherapy was safe ...
New multi-institutional phase 3 clinical trial data published May 2 in Cell Reports Medicine found that a cancer stem cell ...
“ AI-powered algorithms, such as PandaOmics, may accelerate subsequent gene target discovery not only for GBM but for a broader ...
(MIAMI, FL, EMBARGOED UNTIL FEB. 2, 2023 AT 11 A.M. EST) -- Scientists at Sylvester Comprehensive Cancer Center at the ...
BIRMINGHAM, Ala. – IN8bio Inc., a clinical-stage biopharmaceutical company using technology licensed in part from the University of Alabama at ...
